登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
2-(CH3CO2)C6H4CO2H
化学文摘社编号:
分子量:
180.16
UNSPSC Code:
12352106
NACRES:
NA.21
PubChem Substance ID:
EC Number:
200-064-1
Beilstein/REAXYS Number:
779271
MDL number:
InChI key
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
InChI
1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
SMILES string
CC(=O)Oc1ccccc1C(O)=O
grade
analytical standard
form
powder
packaging
vial of 500 mg
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
Quality Level
Gene Information
human ... ITGA2B(3674), PTGS1(5742), PTGS2(5743)
application(s)
forensics and toxicology
pharmaceutical
veterinary
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
通过抑制环氧化酶(前列腺素H合酶),对COX-1亚型具有更高的选择性,阻止前列腺素的产生。抗血栓作用是由于COX-1在血小板中的抑制作用,阻止血栓形成和血小板聚集。 对结直肠及其他实体肿瘤有化学预防作用。
Packaging
棕色螺纹盖样品瓶包装
signalword
Warning
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
482.0 °F
flash_point_c
250 °C
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 3
Niels Hulsman et al.
Journal of medicinal chemistry, 50(10), 2424-2431 (2007-04-20)
Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an antitumor drug. We report that, contrary to
Connie N Hess et al.
Journal of the American College of Cardiology, 66(7), 777-787 (2015-08-14)
Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS). We investigated whether background concomitant antiplatelet therapy influences the effects of apixaban after ACS. This study examined high-risk ACS patients who were treated with aspirin or aspirin plus clopidogrel
Yasuo Ikeda et al.
JAMA, 312(23), 2510-2520 (2014-11-18)
Prevention of atherosclerotic cardiovascular diseases is an important public health priority in Japan due to an aging population. To determine whether daily, low-dose aspirin reduces the incidence of cardiovascular events in older Japanese patients with multiple atherosclerotic risk factors. The
Laurent Arnaud et al.
Autoimmunity reviews, 13(3), 281-291 (2013-11-06)
We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+). Observational and interventional studies identified from the Medline, Embase and Cochrane databases were selected if they
Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
相关内容
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持